Drug resistance in Indian visceral leishmaniasis. - Wikidata - awgldk - TriplyDB

Drug resistance in Indian visceral leishmaniasis.

Drug resistance in Indian visceral leishmaniasis.

http://www.wikidata.org/entity/Q39222666

about

Preventive measures for leishmaniasis Drug repurposing and human parasitic protozoan diseases Multi-modal analysis of courtship behaviour in the old world leishmaniasis vector Phlebotomus argentipes.Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective Advances in Development of New Treatment for Leishmaniasis Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment Developments in the treatment of visceral leishmaniasis Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India Leishmania donovani develops resistance to drug combinations Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression Proteomic and genomic analyses of antimony resistant Leishmania infantum mutant Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study Fitness of Leishmania donovani parasites resistant to drug combinations A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial Drug resistance in leishmaniasis Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads.Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance.Leishmania chagasi T-cell antigens identified through a double library screen Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology Complexities of assessing the disease burden attributable to leishmaniasis.Identification and characterization of a novel deoxyhypusine synthase in Leishmania donovani.Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.

P2860

Q24234937-1DA5D570-3E10-44B1-A3C9-5DA37884A649 Q26999453-F17391F9-FB11-4719-B54A-1C80DF95C583 Q27304685-459DA6C0-95A8-4ABE-A968-FA784D2FBCBE Q28073426-CE43D6BA-DE22-4DDB-9CA3-692D5BA68308 Q28082097-396A5D75-E2D7-4F82-AD10-2240A2A22DED Q28082283-3D8A0F83-C768-4AE7-952D-90B2F7F05C9F Q28256441-88A1C662-4AB7-43FA-B8A6-F400996CA35D Q28468760-1ADCE906-9899-4DAC-BD8E-15F3E1330CBE Q28478242-5C631FBC-082D-46E1-BCD7-EC2329FA6C08 Q28478476-566ECF6C-A64C-49E1-9E79-DAE00D5AA28F Q28482212-31CF0ADA-8BEE-4225-8468-553CFC4C009A Q28482502-67F3A7C5-A26A-44DE-A7A1-E870B689B760 Q28484459-B1F7DF0B-4968-443B-9169-1CCE235E2252 Q28484463-782CB738-0AF7-4350-82D6-A930445AAEBE Q28484622-70FDEBB7-FB65-4B82-9B5A-0708575A59A2 Q28533525-967885C8-454C-4B33-8601-137FDE6EB354 Q28533820-54428420-09F6-4466-974C-8E5A826E2227 Q28535444-1FBAC8E4-56A9-41FD-AFE0-A28F551A804E Q28538265-682AD72E-0876-4AEF-8F02-645AF430DE20 Q28539068-F6614735-B6A8-4A28-BEA0-A80F4924BF0F Q28543060-5BD851B6-D920-401C-9A35-FF75A3253C5E Q28543757-7FC55AF9-BA75-4FC2-A1A4-C7F37802C337 Q28545794-E2B4680B-4330-417B-8B0F-52C62D99E7FB Q28546448-1A916D6D-3CC3-43DB-9DA1-8730F070E682 Q28546699-FC74D7BA-C3EB-4584-8AC3-7BE68C08ABC4 Q28550306-0243D2AC-82F4-490B-99EF-110CC737890F Q28551736-C8A5B6A6-2943-4678-8E83-71FE5E55B616 Q28972231-4B1A7DBA-A98A-4BB0-882D-98C708822892 Q29616242-2EA0004A-AEFE-4BFE-B357-64B4585C2E54 Q30415908-7749CFD1-FA60-456A-BA81-0AB01EC5B96E Q31060208-D71567E8-28D3-4B18-95DC-C89DE2EBCFB2 Q33203657-F7E69877-3A79-4980-859E-458E4160CE42 Q33258365-36739ED6-3373-4720-8A59-9EF47A6C1E54 Q33267301-550EBF4E-4308-45EF-9449-C281D77C44B6 Q33380173-1FC29094-EB4B-4EB7-B68D-4663A9DEE6B3 Q33581343-DF2AE56F-671A-4E45-BCCC-111824352C0A Q33737949-BFE36374-CBD9-408E-B74B-4034247DBC65 Q33786761-2105C2D6-ACBC-4525-9547-8868E67D4DB5 Q33817576-95C955F6-873A-4A9C-8399-A079C445F773 Q33938137-7BF4D8AC-FDF2-4BD3-8545-CD8590A5E502

P2860

Drug resistance in Indian visceral leishmaniasis.

http://www.wikidata.org/entity/Q39222666

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Drug resistance in Indian visceral leishmaniasis.

@en

Drug resistance in Indian visceral leishmaniasis.

@nl

type

label

Drug resistance in Indian visceral leishmaniasis.

@en

Drug resistance in Indian visceral leishmaniasis.

@nl

prefLabel

Drug resistance in Indian visceral leishmaniasis.

@en

Drug resistance in Indian visceral leishmaniasis.

@nl

P1433

Q39222666-FC57D8A6-BB0C-440E-A5B5-F02EA0CC9923

P1476

Q39222666-80233C09-A672-49EB-9484-1124D58D3BD1

P2093

Q39222666-9B3A085C-F50B-4B47-8F27-C80975332150

P2860

Q39222666-0C1F0BD0-705C-4EF0-9ED4-48F0A702B7E4

Q39222666-14924EB5-77F7-42CD-ADD0-37A2B0B7A7B2

Q39222666-19D8D4B2-CED1-4783-93BF-AD58B3B92E24

Q39222666-4E2FEA87-11BB-4931-8EEF-B93F16EDCEE7

Q39222666-4EAD4A4D-7384-40D2-9C2E-1DE2F878180F

Q39222666-4F102B3C-5BE0-4872-A929-0380D4F00B16

Q39222666-5865CA58-837F-45B8-8D95-FD34F25B9383

Q39222666-782BD95A-C219-45E6-8C78-8E425E6D98B9

Q39222666-7DB5F8A8-68F1-4176-940A-4234E1159A0B

Q39222666-C373EA82-93AE-4537-AD00-6A2AF8B2C5EA

P304

Q39222666-AB3DD8E6-7379-4519-9A7E-158437BF1CAA

P31

Q39222666-D8164968-163D-4FC9-9070-0E0C02088D52

P356

Q39222666-7A0662BF-6983-4BD9-BBF7-698B12DB41D1

P433

Q39222666-5ACD72E0-00EB-4EC6-8C24-3A523211560E

P478

Q39222666-ED7AEA1C-1FBF-4FB3-A798-28EE04565345

P577

Q39222666-30E2C42F-F065-4955-B9E5-F267AB1C1D66

P5875

Q39222666-FAB60A4B-BF2B-484B-9A09-D89B4FE3828F

P698

Q39222666-4B5667E8-071A-4C09-960A-F2D151F3309C

P921

Q39222666-C98C8FB8-6D98-41EC-B189-D0330DD6FAD8

Q39222666-F3ED7A08-5E6A-4C70-A70C-461A1D2B8927

P356

J.1365-3156.2001.00778.X

P1433

Tropical Medicine and International Health

P1476

Drug resistance in Indian visceral leishmaniasis.

@en

P2093

Sundar S

http://www.w3.org/2001/XMLSchema#string

P2860

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Trial of oral miltefosine for visceral leishmaniasis

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.

Clinicoepidemiological study of drug resistance in Indian kala-azar.

Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India.

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

P304

849-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-3156.2001.00778.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227907146

http://www.w3.org/2001/XMLSchema#string

P698

11703838

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis